CPSE:GUBRALife Sciences
Gubra (CPSE:GUBRA) Is Down 7.9% After AMX0318 Milestone Deal With Amylyx - Has The Bull Case Changed?
Amylyx Pharmaceuticals recently selected AMX0318, a long-acting GLP-1 receptor antagonist discovered in collaboration with Gubra, as a development candidate for post-bariatric hypoglycemia and other rare diseases, triggering a US$4,000,000 milestone payment and positioning Gubra for more than US$50,000,000 in potential future milestones plus mid-single digit royalties.
The move underlines how Gubra’s partnered peptide programs can translate preclinical research into tangible milestone income...